Formulation and Evaluation of Topical Drug Delivery System

Containing Clobetasol Propionate Niosomes by Abraham Lingan, M
FORMULATION AND EVALUATION OF 
TOPICAL DRUG DELIVERY SYSTEM 
CONTAINING CLOBETASOL PROPIONATE 
NIOSOMES  
Dissertation submitted to 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY, 
CHENNAI
in partial fulfillment of the requirement for the award of degree of 
MASTER OF PHARMACY 
IN
PHARMACEUTICS
March - 2008
DEPARTMENT OF PHARMACEUTICS
MADURAI MEDICAL COLLEGE 
MADURAI 625020.

 CONTENTS
CHAPTER 
NO TITLE
PAGE 
NO
I INTRODUCTION 1
II CONTROLLED DRUG DELIVERY SYSTEM – A REVIEW 4
III NIOSOMES – A REVIEW 12
IV TRANSDERMAL DRUG DELIVERY SYSTEM – A REVIEW 24
V TOPICAL CORTICOSTEROIDS – A REVIEW 36
VI LITERATURE REVIEW 48
VII AIM AND PLAN OF WORK 59
VIII MATERIALS AND EQUIPMENTS 62
IX DRUG PROFILE 64
X EXCIPIENT PROFILE 70
XI EXPERIMENTAL DETAILS 84
XII RESULTS AND DISCUSSION 96
XIII SUMMARY AND CONCLUSION 105
REFERENCES
INTRODUCTION 
Records of medicines and treatment in this world stretch back to 
more than 4500 years. For most of the past centuries the physicians have 
little  real  knowledge,  relied  mainly  on  superstition  and  herbal  cures. 
Knowledge about drugs and diseases starts promptly before 300 years and 
currently there is a drastic change in their development.1 
Even today conventional drug delivery system occupies most of the 
part in a prescription as well as drug store. Even though they release the 
drug promptly, there are some disadvantages.2
DISADVANTAGES OF CONVENTIONAL DRUG DELIVERY2 
1) Slow action.
2) Frequent uptake of drug may lead to patient non compliance.
3) Targeting  or  discontinuance  of  dose  may  lead  to  less  (or) 
prolonged drug therapy.
4) Costly.
To over come the above disadvantages new technologies of drug delivery 
have emerged in the field. 
They are as follows2,
1. Sustained Release.
2. Controlled Release.
3. Targeted Delivery.
Figure - 1
1) Sustained Release 
Sustained release  means the appearance of  the drug in  systemic 
circulation is delayed and/or prolonged and its plasma profile is sustained 
in  duration.  i.e.;  onset  of  pharmacological  action  is  delayed  but 
therapeutic effect is sustained. 
2) Controlled Release
Controlled drug delivery release is the rate of drug delivery which 
is predictable and also the release rate is reproducible from one unit to 
another. 
3) Targeted delivery
The targeted drug delivery means the delivery of drugs by systemic 
administration as drug – carrier complex in the aim of drug delivery at a 
particular diseased cell (or) tissue (or) organ2.
CONTROLLED DRUG DELIVERY SYSTEM
To achieve and maintain  the concentration of administered drug 
within therapeutically effective range, it is often necessary to take drug 
dosage several times and these results are in a fluctuating drug levels in 
plasma. Controlled drug delivery systems are introduced in order to over 
come the above disadvantage of the conventional drug delivery system3. 
Controlled drug delivery systems are the dosage forms which are 
developed to achieve better patient compliance,  modified drug release, 
delivery of drug at  the site of action,  more efficient  administration of 
drugs by various routes and for better therapeutic effect4.
CLASSIFICATION  OF  CONTROLLED  DRUG  DELIVERY 
SYSTEMS5,6 
1. Rate pre-programmed drug delivery system. 
2. Activation modulated drug delivery system.
3. Feed back regulated drug delivery system. 
4. Site targeting drug delivery system.
1. Rate Pre Programmed Drug Delivery System
Here in this system the release of drug molecules from the delivery 
system has been preprogrammed at specific rate profiles. 
Types: 
a. Polymer  Membrane  Permeation  –  Controlled  Drug  Delivery 
System.
b. Polymer Matrix Diffusion – Controlled Drug Delivery System.
c. Microreservoir Partition – Controlled Drug Delivery System.
2. Activation Modulated Drug Delivery System
In this group of controlled drug delivery system the release of drug 
from the delivery device is activated by physical, chemical (or) bio-
chemical process and/or facilitated by the energy supplied externally.
Types
A) Physical means
a. Osmotic pressure – Activated Drug Delivery System.
b. Hydrodynamic pressure – Activated Drug Delivery System.
c. Vapour pressure – Activated Drug Delivery System.
d. Mechanically – Activated Drug Delivery System.
e. Magnetically – Activated Drug Delivery System.
f. Sonophoresis – Activated Drug Delivery System.
g. Ionophoresis – Activated Drug Delivery System. 
h. Hydration – Activated Drug Delivery System.
B. chemical means
i. pH – Activated Drug Delivery System.
ii. Ion - Activated Drug Delivery System. 
iii. Hydrolysis – Activated Drug Delivery System.
C. biochemical means
i.    Enzyme – Activated Drug Delivery System.
ii.   Biochemical – Activated Drug Delivery System.
3. Feed back – regulated drug delivery system 
In this  group of  system the release  of  drug molecules  from the 
delivery system is activated by a triggering agent, such as a biochemical 
substance in the body and also regulated by its concentration via some 
feed back mechanisms. 
a. Bioerosion – regulated Drug Delivery System.
b. Bioresponsive Drug Delivery System.
c. Self regulated Drug Delivery System.
4. Site Targeting Drug Delivery System7
Here  in  this  system  the  drugs  are  particularly  delivered  at  the 
targeted cell, tissue or the organ. The techniques of drug targeting are 
utilization of carriers such as; 
a. Liposomes, 
b. Niosomes,
c. Microspheres,
d. Nanoparticles,
e. Antibodies,
f. Cellular carriers and 
g. Macromolecules.
ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEM6
1. Employ  less  total  drug,  optimize  therapy  and  improved  patient 
compliance,
2. Minimize (or) eliminate local side effects and drug accumulation 
with chronic dosing, 
3. Obtain less potential or reduction in drug activity with chronic use,
4. Improve control of condition i.e; reduce fluctuation in drug level, 
improve bioavailability and treatment efficiencies of some drugs,
5. Make  use  of  specific  drugs  e.g;  sustained  release  aspirin  for 
morning relief of arthritis by dosing earlier, 
6. Maintenance  of  optimum  therapeutic  drug  concentration  in  the 
blood with minimum fluctuations, 
7. Predictable and reproducible release rates for extended duration,
8. Enhancement of activity duration for short half life drug, 
9. Elimination  of  frequent  dosing,  wastage  of  drug  and 
inconvenience of night time administration of drug.
10. Reduction  of  the  incidence,  degree  of  toxicity,  side  effects  and 
irritation of GI tract caused by some orally administered drugs.
DISADVANTAGES  OF  CONTROLLED  DRUG  DELIVERY 
SYSTEM8
1. High cost.
2. Unpredictable (or) poor in-vitro – in-vivo correlation.
3. Dose dumping.
4. Reduce potential for dosage adjustment.
5. Increase first pass clearance.
6. Poor systemic availability in general.
FACTORS INFLUENCING THE DESIGN AND PERFORMANCE 
OF CONTROLLED DRUG DELIVERY SYSTEMS6,8
1) Drug Properties / Physiochemical Properties 
- Partition co-efficient. 
- Drug Stability.
- Protein binding.
- Molecular size and diffusivity.
- Aqueous solubility.
2) Biological Properties 
- Absorption.
- Distribution. 
- Metabolism.
- Elimination and biological half-life.
- Dose size.
- Route of drug delivery.
- Target sites.
- Acute or chronic therapy.
- The pathological disease.
- The patient condition.
- Duration of action.
- Margin of safety.
- Circadian rhythm.
3) Physiological Properties 
- Prolonged drug absorption.
- Variability in GI Emptying and motility.
- Gastro Intestinal Blood flow.
4) Pharmacokinetic Properties 
- Dose dumping. 
- First Pass metabolism.
- Variability of urinary pH effect on drug elimination.
- Enzyme induction/inhibition upon multiple dosing.
5) Pharmacological properties 
- Changes in drug effect upon multiple dosing.
- Sensitizing / tolerance.
DRUGS UNSUITABLE FOR CONTROLLED DRUG DELIVERY8
1. Short / long elimination half life.
2. Narrow therapeutic index.
3. Poor absorption.
4. Active absorption. 
5. Large doses.
6. Low aqueous s solubility.
7. Extensive first pass metabolism.
FUTURE  TRENDS  IN  CONTROLLED  DRUG  DELIVERY 
SYSTEM8
The most exciting and challenging opportunities in controlled drug 
delivery lie in the arena of responsive delivery system, with which it will 
be possible to deliver drug through implantable devices in response to a 
measured blood level and to deliver the drug precisely to a target size. 
NIOSOMES – A REVIEW
CHAPTER III
NIOSOMES 
Paul  enlrich,  who  coined  the  term ‘Magic  bullet’  in  early  20th 
century, where a carrier  system was proposed to simply carry to its site 
of  action  and  releasing  it  selectively  while  non-target  sites  should 
absolutely be exempted from drug effect. This concept is proved in case 
of liposomes9. 
Liposomes were discovered in the early 1960’s by Bangham and 
colleagues and subsequently became the most extensively explored drug 
delivery system10. Liposomes are concentric bilayered vesicles in which 
an aqueous volume is entirely enclosed by a membranous lipid bilayer 
mainly composed of natural (or)  synthetic phospholipids and cholesterol.
But there are some limitations in Liposomal delivery system.
DISADVANTAGES OF LIPOSOMES10,11
1. Liposomal  phospholipid  undergo  chemical  degradation  such  as 
oxidation and hydrolysis. 
2. Liposomes in  aqueous suspension may aggregate,  fuse  (or)  leak 
their contents.
3. Cost of natural phospholipids are usually high.
4. Purity of natural phospholipids is always doubtful.
5. Due  to  oxidative  degradation  they  should  be  stored  in  nitrogen 
atmosphere.
6. The  phospholipids  will  interact  with  serum  components  (High 
density lipoprotein). These high density lipoprotein will remove the 
phospholipids from the vesicles and lead to leakage of drugs.
7. Liposomal formulations are expensive.
Due to the  above demerits  of  liposomes,  a  new vesicular 
system emerged known as Niosomes. 
NIOSOMES  (Non Ionic Surfactant Vesicle)
Niosomes are non-ionic surfactant vesicles first initiated by Ballie 
et.al  in  1985.  Niosomes are  concentric  bilayered vesicles  in  which an 
aqueous  volume  is  entirely  enclosed  by  a  membranous  lipid  bilayer 
mainly composed of non-ionic surfactants and cholesterol.
Figure - 2
ADVANTAGES OF NIOSOMES7,10,11
1. Stability of niosomes are better than liposomes.
2. Niosomes can prolong the circulation of entrapped drugs.
3. Due to the presence of non-ionic surfactant, the targeting nature 
of drugs to brain and liver and also for tumour are better. 
4. So due to the presence of better targeting nature it is proved that 
usage of niosomal technology in treating cancer, parasitic, viral 
and other microbial disease are more effective. 
5. Non-ionic surfactant will increase both fluidity and permeation of 
biological membranes.
6. Niosomes are non-ionic and also biodegradable.
7. Niosomes reduce systemic toxicity of drugs such as anti-cancer, 
anti-infectives etc.
8. As a  carrier  for  enhanced  drug  delivery  to  specific  cells  they 
improve the therapeutic index by restricting the drug effects to 
target cells.
9. Niosomes could serve as intramuscular cargo and depots for short 
acting peptide drugs which are cleared fast from the circulation.
10. These systems are potent stimulators of the cellular and humoral 
immue response.
11. The formulation of antigen as a niosome in w/o emulsion further 
increases the activity of antigens.
12. Compared to liposomes, usage of non-ionic surfactant instead of 
phospholipids have better chemical stability, precise in chemical 
composition and cheaper in cost.
13. Niosomes can enhance the skin penetration of drugs.
TYPES OF NIOSOMES11
They are divided intro three types. They are as follows; 
a) Small Niosomes (100 nm to 200 nm)
b) Large Niosomes (800 nm to 900 nm)
c) Big Niosomes (2µm to 4 µm)
BASIC COMPONENTS OF NIOSOMES 
1. Non-ionic surfactant (or) Amphiphilies.
2. Cholesterol.
3. Drug.
4. Distilled water (or) Buffer.
METHODS OF PREPARATION7,10,12,13 
1. Hand Shaking Method.
2. Ether Injection Method.
3. Sonication Method.
4. Reverse Phase Evaporation Method.
5. Aqueous Dispersion Method. 
6. Extrusion Method.
7. Microfludization Method.
8. Thin Film Hydration Method.
9. Transmembrane pH Gradient Method.
1) Hand Shaking Method 
In  this  method  surfactant  and  cholesterol  are  mixed  in  organic 
solvent  and  the  organic  layer  is  transferred  to  round bottom flask  by 
vacuum.  Then it  is  allowed to evaporate in round bottomed flask and 
upon hydration the surfactant swells to form vesicles. 
2) Ether Injection Method 
Here  the  vesicles  are  formed,  when  the  surfactant:  Cholesterol 
mixture in organic solvent is slowly injected by a 14 guaze needle at a 
rate of 0.25 ml/min in aqueous phase maintained at 600C.
3) Sonication Method
In this method surfactant: Cholesterol mixture was dispersed in a 2 
ml of aqueous phase in a vial. Then the dispersion was probe sonicated 
for 3 minutes at 600C.
4) Reverse phase evaporation method 
Surface active agents are dissolved in chloroform and 0.25 volume 
of phosphate buffer saline is emulsified to get w/o emulsion. The mixture 
is  then  sonicated  and  subsequently  chloroform  is  evaporated  under 
reduced  pressure.  The  lipid  (or)  surfactant  forms  a  gel  first  and 
subsequently hydrates to form vesicles. 
5) Aqueous Dispersion Method 
This method essentially based on microdispersion of surfactants in 
aqueous  media  containing  solutes  for  encapsulation  (or)  entrapment. 
Continuous  agitation  under  controlled  temperature  condition  leads  to 
homogenous vesiculation.
6) Extrution Method 
Niosomes were prepared by using C16 Cr2 a chemically defined 
non-ionic surfactant by extrution through a Polycarbonate membrane (0.1 
mm nucleopore)
7) Microfludization Method 
This  method  is  based  on submerged  jet  principle  in  which two 
fluidized streams interact  at  ultra  high velocities  (upto 1700 ft/sec)  in 
precisely  defined  micro  channels  within  the  interaction  chamber.  The 
impingement of thin liquid sheets along a common front is arranged such 
that  the  energy  supplied  to  the  system  remains  with  in  the  area  of 
niosome formulation. 
8) Thin Film Hydration Method 
The surfactant : Cholesterol mixture is dissolved in volatile organic 
solvent and the solvent is evaporated in round bottom flask at 600C until a 
thin film was formed. Then aqueous solvent is added and vortexed for 1 
hour. The film peels off and later swells to form niosomes. 
9) Transmembrane pH gradient Method 
Here the surfactant and cholesterol were dissolved in chloroform. 
The solvent was evaporated on the walls of round bottom flask. The film 
is hydrated with 300 mm citric acid by vortex mixing. Then the product 
was frozen. To this niosomal suspension, aqueous solution was added and 
vortexed. The pH of the solution was raised to 7.0 to 7.2 with 1ml of 
disodium hydrogen phosphate. The mixture was later heated at 600C for 
10 minutes. 
SIZE, SHAPE AND MORPHOLOGY10,13,14
Vesicular structure of surfactant based vesicles has been visualized 
and established using freeze fracture electron microscopy while photon 
correlation spectroscopy could be successfully used to determine mean 
diameter of the vesicles. 
The  vesicles  can  also  be  examined  using  light  microscope, 
polarized light microscope, Olympus microscope, infrared spectroscopy 
and electron microscopy.
ENTRAPMENT EFFICIENCY 10
For finding entrapment efficiency the vesicles have to be lysed and 
made upto the volume by suitable solvent. For the vesicular disruption 
the following chemicals can be used: 
- Hydrophilic surfactant solulan C24
- Triton X-100
- 0.2% desoxycholate
- 50% propanol
The Entrapment efficiency can be found out by the following formula. 
Entrapment efficiency = % Drug content - % of maximum drug 
release of unentrapped 
drug.
Effect Of Cholesterol In Niosomes16
Cholesterol  plays  an  important  role  in  absolute  encapsulation 
efficiency of the formulation and in turn the stability of niosomes.
However after certain concentration the intercalation of cholesterol 
in  the  bilayers  decreases  the  entrapment  volume  and  thus  entrapment 
efficiency.  Therefore  increase  in  the  concentration  of  cholesterol 
decreases the entrapment  efficiency.
And  also  after  certain  concentration  the  increase  in  cholesterol 
content  decreases  the  maximum  rigidity  of  niosomal  membrane 
properties. 
Effect Of Surfactant In Niosomes17 
Surfactants  are ‘Surface Acting  Agents’  (wetting agents)  which 
lowers the surface tension of a liquid. 
Various  surfactants  are  used  in  the  niosomal  preparation  are 
Span’s, Tween’s and Brij’s.
The mean size of niosomes increases when increase in HLB value 
of span. [Span 85 to span 20 respectively]. 
Entrapment efficiency increases when increase in phase transition 
temperature. Since phase transition temperature of Span 60 was greater 
than Span 40, Span 60 shows more entrapment efficiency when compared 
with Span 40.
The  entrapment  efficiency  increases  with  increase  in  the 
concentration  and  lipophilicity  of  the  surfactant.  But  the  entrapment 
efficiency  of  Span 80 was less  when compared  with Span 60,  this  is 
because of the presence of unsaturated alkyl chain in Span 80. 
STABILITY OF NIOSOMES10
Studies  showed  that  the  niosomal  preparations  are  stable 
comparatively than the liposomal preparations. 
Osmotic Effect15
Addition  of  hypertonic  salt  solution  to  suspension  of  niosomes 
brings about reduction in vesicle diameter with concominant water efflux, 
which  may  be  due  to  pumping  out  of  vesicle  content  where  as  in 
hypotonic salt solution there is initial slow release with slight swelling of 
vesciles probably due to inhibition of eluting fluid from vesicles followed 
by faster  release,  which may  due  to  mechanical  loosening of  vesilces 
under osmotic stress. 
Stability In Vivo
Moser and colleagues 1980 studied plasma protein interaction with 
haemoglobin  containing  niosomes.  There  was  no  agglutination. 
Haemoglobin  niosomes  are  found  to  be  stable,  however  they  are 
chemically  instable,  i.e;  oxidation  of  haemoglobin  to  methaemoglobin 
was recorded as a result of haemoglobin content reached about 30% after 
5 months at 40C
TOXICITY OF NIOSOMES 
There was no toxic reports yet filed due to the usage of niosomes 
as drug carriers in animals.  But however the toxic effects  are directly 
related to the type of drug released. 
LIST OF NIOSOMALY ENTRAPPED BIO ACTIVE AGENTS10 
Various  bioactive  agents  which  are  entrapped  in  niosomes  are 
sodium  stilbogluconate,  Methotrexate,  vincristine,  doxorubicin, 
diclofenac sodium, bovine serum albumin, s9-Desglycinamide 8-Arginine 
vasopressin, insulin, estradiol, antipyrine, rifampicin, Haemoglobin. 
APPLICATIONS OF NIOSOMES10,16,18
Niosomal  drug  delivery  is  potentially  applicable  to  many 
pharmacological  agents  for  their  action  against  diseases.  By  niosomal 
formation we can potentially deliver both hydrophobic (or) amphiphilic 
drugs. 
1. Targeting of bioactive agents to reticulo endothelial system and 
to organs other than reticulo endothelial system. 
2. Used in Neoplasia. 
3. Used in Leishmaniasis.
4. Used to delivery peptide drugs.
5. Used in immunological applications.
6. Used as a carrier of haemoglobin.
7. Used in Transdermal drug delivery of drugs. 
8. Used in Diagnostic imaging. 
9. Used in oral drug delivery.
10. Useful in sustained release and localized drug action. 
CHAPTER – IV
TRANSDERMAL DRUG DELIVERY SYSTEM
INTRODUCTION 
Transdermal  drug  delivery  system is  one  among  of  the  various 
modes of drug delivery which facilitates passage of therapeutic quantities 
of drug substances through the skin and for systemic (or) local effects19. 
Discovering  a  new  medicine  is  a  very  expensive  and  time-
consuming work. But however, redesigning the modules and means to 
transport medicine into the body is a less demanding and more lucrative 
task. 
In the normal drug release, if the medication may not be absorbed 
means it will release too slowly (or) if it delivered too fastly means, the 
patient may suffer untoward effects. To rectify the above drawback one 
of the solutions developed was transdermal drug delivery systems20.
SKIN21
Figure - 3
Skin is the largest organ of 1.5 to 2 m2 in adult which covers the whole 
body.  Thickness of skin varies from place to place i.e; it is so thick in 
palm, foot and so thin in eyelid. 
The  skin  is  broadly  classified  into  two  layers.  They  are;  A) 
epidermis and B) Dermis.
A. Epidermis
It is the most superficial (or) outermost layer of skin. The cells in 
the  epidermis  shed  periodically  and  replaced  by  new  cells  usually  a 
complete replacement of epidermis takes about 40 days.
Various Layers In Epidermis 
There are about four layers. They are; 
i. Stratum corneum.
ii. Stratum lucidum.
iii. Stratum granulosm. 
iv. Germinative layer. 
B. Dermis
Dermis consists of the following things in it 
- Blood vessels.
- Lymph vessels.
- Sensory (somatic) nerve ending.
- Sweat glands and their ducts.
- Hair roots, hair follicles and hairs.
- The arrectores pilorum – involuntary muscles attached to the hair 
follicles.
- Sebaceous glands.
Heirs, secretions from sebaceous glands and ducts of sweat glands 
pass via the epidermis to reach the surface. 
FUNCTION OF SKIN 
It does major functions to the human body. They are;
- Mechanical function 
- Protective function 
• microbiological barrier
• Chemical  barrier
• Radiation barrier 
• Electrical Barrier 
- Regulation of body temperature
- Formation of vitamin D
- Sensation 
- Absorption 
- Excretion 
RATIONAL APPROACH TO DELIVER THE DRUG VIA SKIN22 
Figure - 4
There  are  three  main  ways to  approach the  problem of  formulating  a 
successful topical dosage form. 
1. Manipulating the barrier function of the skin 
2. Directing  drugs  to  the  viable  skin  tissues  without  using  oral, 
systemic (or) other routes. 
3. Using skin delivery for systemic treatment. 
Dermatologist aim five main target regions. They are skin surface, horny 
layer,  viable  epidermis  &  upper  dermis,  skin  glands  and  systemic 
circulation. 
Figure – 5
FACTORS AFFECTING DRUG DELIVERY 
Transdermal route should have the capability to deliver the drug, 
regardless of  size  (or)  structure at  a  predetermined rate.  But  there  are 
some factors which influence the rate of drug delivery.  There are two 
types of factors
They are as follows 
A. Biological factors 
- Skin condition. 
- Skin age.
- Amount of blood flow.
- Regional Skin sites.
- Skin metabolism.
- Species differences.
B. Physiochemical Factors 
- Skin hydration.
- Temperature and pH
- Diffusion Coefficient
- Drug applying surface area.
- Drug Concentration.
- Partition Coefficient. 
– Molecular size and shape.
–
TYPES  OF  TREATMENT  ACHIEVED  BY  TOPICAL  DRUG 
DELIVERY 
- Camouflage.
- Protection effects,.
- Insect repellant.
- Antimicrobial.
- Antifungal.
- Emolliency. 
- Keratosis.
- Antiperspirant.
- Exfolient.
- Antibiotic.
- Depilatory.
- Anti inflammation.
- Anti pruritic.
- Local anesthetic.
- PUFA and PDT.
- Anti histamine.
- Anti angina.
- Anti-ischaemic.
VARIOUS TYPE OF DOSAGE FROM USED IN TOPICAL DRUG 
DELIVERY
- Liquid preparations.
- Gels (jellies).
- Powders.
- Ointments.
- Creams.
- Paste.
- Aerosols.
- Poultice.
- Transdermal patch.
METHODS TO INCREASE PERCUTANEOUS ABSORPTION20 
Chemical penetration enhancers such as – 
- Solvents 
- Alkyl Methyl sulphoxides
- pyrrolidones
- Azone and related compounds
- surfactants 
- Ionophoresis
- Sonophoresis
- Electrophoresis
- Laser Ablation
- prodrugs 
ADVANTAGES  OF  TRANSDERMAL  DRUG  DELIVERY 
SYSTEM20
1. Avoidance of significant presystemic metabolism (degredation in 
GI tract (or) Liver, gut wall) and the daily drug dose is reduced. 
2. Reduction of Inter and Intra Patient variability. 
3. Drug level  can be maintained in systemic  circulation within the 
therapeutic window. 
4. Drug  action  is  extended  and  frequency  of  administration  is 
reduced. 
5. Improved patient compliance. 
6. Drug input can be easily terminated.
7. Increased safety. 
8. Greater convenience.
9. Drugs with short biological half lives.
DISADVANTAGES  OF  TRANSDERMAL  DRUG  DELIVERY 
SYSTEM20 
1. Skin irritation. 
2. Skin allergy.
3. Potent drugs cannot be given by this route.
ROLE OF NIOSOMES IN TRANSDERMAL  DRUG DELIVERY 
SYSTEM23 
Niosomes can be used to deliver both hydrophobic and hydrophilic 
drugs via transdermal route. Although niosomes were tried for various 
routes it is used in the market for transdermal route (Novasome Products 
Such  as  30%  Petrolatum  Novasomes  and  10%  Salicyclic  Acid 
Novasomes). Studies showed that an enhanced delivery of drugs when 
encapsulated in niosomes. Niosomes increase skin penetration of drugs 
and  it  can  act  as  local  depot  for  sustained  release  of  dermally  active 
compounds. When non ionic surfactants are incorporated into niosomes 
they are much better tolerated by the skin then when they are used in 
emulsion.  
VARIOUS  BIO  ACTIVE  AGENTS  WHICH  ARE  TRIED  VIA 
TRANS  DERMAL  ROUTE  AS  NIOSOME  DRUG  DELIVERY 
SYSTEM23,24,25,26,27,28,29
- Cyclosporin – A.
- Lidocaine.
- Estradiol.
- Erythromycin.
- Alpha – interferon.
- Diclofenac sodium. 
- Nimesulide.
- Enoxacin.
- Miconazole nitrate.
- Ketoconazole.
- Tretionin.
- Metronidazole. 
CHAPTER – V
TOPICAL CORTICOSTEROIDS 
CORTICOSTEROIDS 
INTRODUCTION 21
The  adrenal  (or)  supra  renal  glands  present  above  each  kidney 
secrete  the  steroidal  hormones.   Two types  of  steroidal  hormones  are 
Glucocorticosteroids and mineralocorticosteroids
HISTORY OF CORTICOSTEROIDS30,31
By the  middle  of  19th century  it  was  demonstrated  that  adrenal 
glands  were essential  for  life.  A number  of  steroidal  active principles 
were  isolated  and their  structures  were  elucidated  by Kendall  and his 
coworkers  in  1930s.  However  isolation  of  “cortisone”  by  Kendall, 
Reichstein and Hench was a remarkable event in corticosteroids and they 
got noble prize for medicine in 1950.
General Chemical Structure of corticosteroids 
Figure – 6
ACTIONS OF GLUCOCORTICOSTEROIDS31
1. Effects on carbohydrate metabolism.
2. Effects on protein metabolism.
3. Effects on fat metabolism.
4. Effects on calcium metabolism.
5. Effects on water excretion. 
6. It restricts capillary permeability and maintains tone of arterioles & 
myocardial contractibility.
7. Effects on skeletal muscles for normal muscular activity.
8. Mild euphoria is quite common with glucocorticosteroids. 
9. It increases the gastric acid and pepsin secretion.
10. It increases the number of red blood cells, platelets and neutrophils 
in circulation.
11.Irrespective of the type and cause of injury the glucocorticoids will 
suppress the inflammatory response. 
12. It  will  suppress   all  types  of  hyper  sensitization  and  allergic 
phenomena. 
TOPICAL CORTICOSTEROIDS32
INTRODUCTION 
With the introduction of topical steroid for the treatment of skin 
diseases, the phase of dermatological therapy changed drastically. From 
the period of Sulzberger and Witten, experiments had started to increase 
the  potency  and  to  reduce  the  side  effects.  This  resulted  in  the 
introduction of a number of molecules. As the search is going on and the 
“ideal” topical steroid has not been found, newer and newer molecules 
are being introduced one after another. 
HISTORY
The development from the discovery of the structure of cholesterol, 
the precursor of all steroids, to the first application of a topically effective 
steroid in 1952 it  took about 20 years.  Encouraged by this success of 
systemically  administered  corticosteroids,  people  started  to  experiment 
with  topical  application  of  steroid.  The  first  molecule  they  tried  was 
cortisone acetate, which was a miserable failure. During this time Merck 
& Co. Made “Compound F” and Sulzberger and Witten incorporated it in 
an ointment base (25 mg of base). The ‘Compound F’ was hydrocortisone 
acetate.  They  used this  ointment  in  a  number  of  conditions  including 
atopic dermatitis, psoriasis, chronic discoid lupus erythematosus, chronic 
lichenoid  dermatoses,  pemphigus  vulgaris,  and  alopecia  areata.  The 
reports of this trial appeared in the journal of investigative dermatology in 
1952  and  were  the  turning  point  in  the  history  of  topical  therapy  in 
dermatology. Since then newer and newer molecules were added with 
variations  in  efficacy  and  side  effect  profile  and  now we  have  super 
potent corticosteroid. 
PHARMACOLOGY
The  clinical   effects  of  topical  corticosteroids  depend  on  the 
structure  of  the  molecule,  the  vehicle  and  the  skin  onto  which  it  is 
applied. 
All  steroids  have  the  basic  4-ring  structure  of  cholesterol,  with 
three hexane ring and one pentane ring. Modifications in the basic 4-ring 
structure result in various agents with differing solubility, lipophilicity, 
percutaneous  absorption  and  glucocortiocoid  receptor  binding activity. 
Addition of a fluorine molecule at positions 6 and / or 9 enhances the 
potency of steroid. Removal, replacement or making of hydroxyl groups 
increases  the  molecules  lipophilicity.  This  facilitates  percutaneous 
absorption as well as glucocorticoid receptor binding activity. 
By covering the skin with an occlusive dressing such as a plastic 
wrap, this effect can be heightened as much as 100-fold. The solubility of 
glucocorticoid in the vehicle also affects penetration into epidermis. 
The condition of skin also affects bioavailability. Penetration of the 
applied  drug  is  inversely  proportional  to  the  thickness  of  stratum 
corneum. It increases if the drug is applied over an inflamed or diseased 
skin. Penetration also depends on the humidity and temperature of the 
environment.  The  stratum corneum may  act  as  a  reservoir  for  topical 
corticosteroids  and  this  is  dependent  on  topical  corticosteroids 
concentration and formulation. 
CLASSIFICATION 
There  are  a  number  of  topical  corticosteroids  available  for  use. 
There are two important systems of classification; one of which classifies 
topical corticosteroids into seven classes-VII has the mildest ones (Table 
1).  The other classification is the one adopted by the British National 
Formulary and employs a four-point scale of mild, moderate, potent and 
very potent, to classify these agents (Table 2). 
TABLE. 1. CLASSIFICATION OF TOPICAL 
CORTICOSTEROIDS 
Class Drugs
Class I (Super-Potent) Clobetasol propionate, Halobetasol propionate, 
Betamethasone dipropionate 0.05% ointment 
(optimized vehicle)
Class II (Potent) Mometasone furoate ointment Halcinonide 
Fluocinonide 
Class III (Potent) Fluticasone propionate, Betamethasone 
dipropionate Cream (0.05%) 
Class IV (Mild – 
strength)
Mometasone furoate cream (0.1%) Triamcinolone 
acetonide cream (0.1%) Betamethasone valerate 
foam (0.12%)
Class V (Mild – 
strength)
Flurandranolide 0.05%) Betamethasone 
dipropionate lotion (0.05%) Hydrocortisone 
butyrate (0.1%)
Class VI (Mild) Desonide cream (0.05%)  Fluocinolone acetonide 
0.01% cream
Class VII (Mild) Topicals with hydrocortisone, dexamethasone 
 
Table 2. Classification used by British National Formulary 
Potency Drugs
Very Potent Clobetasol propionate (0.05%), Fluocinolone 
acetonide (0.2%) Halcinonide (0.1%)
Potent Betamethasone valerate 0.1% and 0.25% 
Mometasone furoate % Desonide % 
Moderately potent Beclomethasone dipropionate (%) Clobetasone 
butyrate 0.05% 
Mild Dexamethasone 0.1-0.2% Methylprednisolone 
acetate 0.25%
Both these classifications are good. But the author prefers the four point 
classification while choosing the corticosteroid preparation because of the 
ease of clinical application and predictability of effects as well as side 
effects. 
MECHANISM OF ACTION 
Glucocorticoids  diffuse  through  stratum  corneum  barrier  and 
through cell membranes to reach the cytoplasm of keratinocytes and other 
cells present in epidermis and dermis. Diffusion through stratum corneum 
is  the  rate  limiting  step  in  delivery  of  the  drug.  Once  it  reaches  the 
cytoplasm,  glucocorticoids  binds  to  a  specific  receptor  glucocorticoid 
receptor.  The binding of the receptor to its ligand results in activation of 
the receptor, which dissociates from other components of the tetrameric 
complex. The ligand bound receptor then enters the nuclear compartment 
and  interacts  with  specific  response  elements  on  the  genome, 
glucocorticoid  response  elements.  This  modulates  transcription  of 
numerous  genes.  In  contrast  to  the  positive  gene  regulation, 
glucocorticoids  can  supress  gene  activation  by  several  mechanisms 
including interfering with function of transacting factors. 
The above interactions lead to changes in the expression of a wide 
range  of  genes,  resulting  in  diverse  cellular  effects,  which  includes 
suppression of production of inflammatory cytokines, inhibition of T-cell 
activation, changes in the function of endothelial cells, granulocytes, mast 
cells and fiborblasts and inhibition of proliferation. 
The transcription activity of the steroid receptor seems likely to be 
regulated  by  an  alternative  isoform  of  the  receptor  known  as 
glucocorticoid  receptor  β  and  it  is  an  endogenous  inhibitor  of 
glucocorticoid action. 
Lipocortin,  interleukin (IL-1) and lymphokines  such as IL-2 are 
some  of  the  proteins  induced by  the  steroid.  Lipocortin  is  capable  of 
inhibiting the A2 phospholipase and reducing liberation of arachidonic 
acid which in turn reduces inflammatory response. 
IL-1 has a role in inflammation. The in-vitro exposure of human 
keratinocytes  to  hydrocortisone  decreases  the liberation of  constitutive 
IL-1 as well as IL-1 induced keratinocytes to hydrocortisone decreases 
the  liberation  of  constitutive  IL-1  as  well  IL-1  induced  by  ultraviolet 
radiation.  This  would  also  explain  the  anti-inflammatory  and  anti-
proliferation effect of the drug.
The glucocorticoids have an immune suppressive action for B-and 
T-lymphocytes as well as over monocytes/macrophages. They also cause 
depletion of the number of Langerhans’ cells. 
SIDE EFFECTS 
The side effects of topical corticosteroids are inevitable; 
Local side effects 
 Skin atrophy.
 Contact allergy.
 Steroid roascea and periora dermatitis.
 Rise in intraocular pressure.
 Depigmentation/Hypopigmentation.
Systemic side effects 
 Hypothalamopituitary adrenal axis. 
PAEDIATRIC USE
Topical  corticosteroids  are  used  with  caution  in  children.  The 
general principle is to use as mild a steroid as possible, for as short a 
period as possible, over as small area as possible. 
USE IN PREGNANCY
Appropriate  human  studies  using  topical  corticosteroids  in 
pregnancy  have  never  been  undertaken.  However,  numerous  pregnant 
patients  are  using  glucocorticosteroids  throughtout  pregnancy  without 
any problem to the infant. 
FORMULATIONS
There are a number of topical corticosteroids preparations available 
in the market. 
The topical corticosteroids for dermatological use are available as 
ointments,  creams,  lotions,  gels  and  foam.  Ointments  enhance  the 
percutaneous absorption of topical corticosteroids by increasing hydration 
and temperature of skin. Creams use emulsions of water-in-oil or oil-in-
water with the active agent dispersed between oil and water phase. They 
do not retard loss of heat or feel greasy. Lotions are a mixture of powder 
and liquid in an aqueous or alcoholic suspension, and gels are transparent 
semisolid emulsions that liquefy on contact with warm skin, drying as a 
greaseless, non-occlusive film. 
COMBINATIONS 
Several  antimicrobials  are  commercially  formulated  in 
combination  with  topical  corticosteroids.  The  usual  drugs  used  are 
antibiotics and antifungals. 
DILUTING READY MADE PREPARATIONS 
The  practice  of  diluting  ready  made  preparations  with  another 
agent is not a welcome practice. With dilution, the bioavailability of a 
topical  corticosteroids  may  be  altered.  Dilution  may  also  introduce 
contamination. 
TOPICAL STEROIDS IN CLINICAL PRACTICE
To have an appropriate response, the drug must be used judiciously 
as well as for sufficiently longer period. It is often observed that there is a 
premature withdrawal of topical corticosteroids. This will result in relapse 
of the disease. 
PRACTICAL POINTS 
 Use topical corticosteroids judiciously. 
 Use steroid for sufficiently longer time so that there is remission of 
the condition. 
 Wean –off steroid if used for more than one month. 
 Give steroid holiday.
 For thick lesions – steroid + salicylic acid.
 For  flexors  –  moderately  potent  steroid;  avoid  highly  potent 
steroid. 
 For hairy region – solution/foam.
 Avoid topical corticosteroids over oozing lesion.
 For subacute dermatitis – creams.
 For Chronic lichenified lesion – ointment.
 For Children – as mild a steroid as possible, for as short a period as 
possible, over as small an area as possible. 
CHAPTER VI
LITERATURE REVIEW 
1) A.J.  Baillie  and  A.T.  Florence  et.al.,  formulated  Niosomes  by 
hydrating a mixture of single (or) double alkyl chain non ionic 
surfactant with cholesterol.  They found that these vesicles can 
retain  water  soluble  solutes  such  as  carboxyfluorescein  and 
release the entrapped solute slowly. The vesicles were prepared 
by Ether injection, Hand shaking and Sonication methods. The 
vesicles  size  were  characterized  by  Proton  correlation 
spectroscopy33. 
2) A.R. Mullaicharam and R.S.R. Murthy formulated and optimized 
Rifampicin Niosomes. They studied about the effect of change in 
process  variable  such  as  volume  of  solvent,  hydration  time, 
volume of hydrating medium and sonication time were studied. 
The prepared Niosomes were characterized for size, shape and 
lamellarity34. 
3) S.Bhaskaran and L. Panigrahi formulated and evaluated Niosomes 
using different non-ionic surfactants. Such as Span 20,40,60,80, 
Tween  20,  40,  60,  80  and  Brij  35,  The  vesicle  size  were 
characterized  by IR spectroscopy.  They  found  that  among  all 
span 60 showed maximum release in 24h35. 
4) P.M.  Sattur  war  et.al.,  formulated  and  evaluated  ketoconazole 
Niosomes by Ether  injection  method.  The prepared Niosomes 
were  characterized  for  size,  shape,  entrapment  efficiency  and 
invitro drug release. In-vivo antifungal activity was also tested in 
rabbits36. 
5) H.E.J. Horland et.al., studied about the safety aspects of Niosomes. 
Two  different  toxicity  models  were  used  to  assess  the 
relationship  between  the  physiochemical  properties  were 
described in terms of HLB values and CMC. Neither the HLB 
nor the CMC values appeared to have an effect on the safety of 
Niosomes as observed in both toxicity models37. 
6) Yongmei Hao et.al., studied about the best surfactant among span 
series  in  the  aspect  of  encapsulation  capacity.  They  used 
colchicines as a model  drug. They found span 60 is the most 
ideal surfactant among all the four by surfactants in span series38. 
7) J.N.Khandare and G.Madhavi formulated and evaluated ketoprofen 
Niosomes. They used Non-ionic surfactants such as Tween 20, 
40 and 80. Among the three they found Tween 40 showed more 
entrapment  efficiency  in-vivo  anti-inflammatory  activity  was 
studied by Paw oedema method39. 
8) S.K  shah  et.al.,  prepared  and  evaluated  miconazole  nitrate 
Niosomes. They found Hand shaking method is a ideal one. And 
also Niosomal gel is better than plain gel. They concluded that 
Niosomal  gel  releases  the  drug  slowly  and  increase  retention 
time  and  this  may  restrict  the  entry  of  drug  into  systemic 
circulation40. 
9) Alok  Namdeo  et.al.,  formulated  and  evaluated  the  Niosomally 
encapsulated  Indomethacin.  Size  of  the  Niosomes  were 
characterized  by  light  and  scanning  microscope.  The  Anti-
inflammatory activity was studied by Paw-oedema method41. 
10) Agrawal sunil  et.al.,  studied about the Niosomal  Daunorubicin’s 
anti-cancer  activity  in  swiss  mice  bearing  fibrosarcoma. 
Niosomes  were  prepared  by  Solvent  dispersion  method.  The 
formulated  Niosomes  were  characterized  for  size,  entrapment 
efficiency and in-vivo drug release. Finally they proposed that 
encapsulation of daunorubicin in Niosomes is a potential tool for 
the effective delivery of drug42.
11) D.Saravanan and H.Popli  prepared  and evaluated  Metronidazole 
loaded  Niosomes  in  rats.  Niosomes  were  prepared  by  Hand 
Shaking  method.  Higher  concentration  of  metronidazole  were 
achieved in liver when the drug was entrapped in Niosomes and 
the  Niosomes  could  be  considered  as  potential  carriers  for 
hepatic localization of Metronidazole43. 
12) M.  carafa  et.al.,  prepared  and  evaluated  the  properties  of 
Niosomes.  Niosomes  were  prepared  by  Polysorbate  20  and 
Cholesterol  by  using  two  different  methods  such  as  Direct 
Sonication and Thin film hydration method. They found higher 
entrapment efficiency in Thin film hydration method. Vesicles 
were characterized for vesicle dimension, entrapment efficiency 
and stability44. 
13) J.N.  Khandare  et.al.,  discussed  about  the  disadvantages  of 
liposomes,  advantages  of  Niosomes  and  factor  affecting  drug 
entrapment and release characters45. 
14) S.  Agarwal et.al.,  studied about the effect  of cholesterol  content 
and  surfactant  on  vesicle  properties  of  Niosomes.  Niosomes 
were prepared using Primaguine phosphate as a model drug by 
mechanically  shaking  method  without  sonication.  The 
Entrapment efficiency was increased with increasing cholesterol 
content.  Mean  size  of  Niosomes  were  also  increased  in 
increasing HLB value (span 85  span 20)46.
15) K.  Ruckmani  et.al.,  formulated  Niosomes  using  Cytarabine 
Hydrochloride.  The  Niosomal  vesicles  were  formulated  using 
Lipid hydration method. The sizes were obtained ranging from 
600 to 1000 nm. The entrapment efficiency was high upto 80% 
with  Tween  80,  20  and  Span  60.  The  physical  stability  of 
Niosomes were good over a period of 4 weeks47. 
16) Ambikanandan  Misra  et.al.,  studied  about  the  topically  applied 
Nimesulide  Niosomes  were  formulated  using  Lipid  film 
hydration  technique.  Prepared  Niosomes  were  optimized  for 
high  entrapment  efficiency.  Then  the  Niosomes  were 
incorporated  into  gel  and  Anti  –  inflammatory  activity  was 
checked  by  Paw  oedema  method.  Niosomally  entrapped 
Nimesulide shows highest paw edema inhibition48.
17) V.Ravichandran et.al., prepared and evaluated the in vitro release 
of  Diclofenac  sodium niosomes.  Niosomes  were  prepared  by 
Hand  Shaking  method  and  Ether  injection  method.  The 
Niosomes  were  subjected  for  vesicle  size  determination  and 
entrapment  efficiency.  Hand  Shaking  method  showed  high 
entrapment  efficiency  when  compare  to  Ether  injection 
method49.
18) N.K.Jain and Manjusha malhotra discussed about various method 
of  preparation  of  Niosomes,  in  vitro  characterization  such  as 
vesicle diameter, entrapment efficiency, osmotic shrinkage, drug 
release  and  route  of  administration  including  applications  of 
Niosomes50.
19) C.P.  Jain  et.al.,  studied  about  Niosomal  drug  delivery  of 
Rifampicin to lymphatics. The Niosomes were prepared by Thin 
film  hydration  method.  The  vesicles  were  characterized   for 
shape, size, entrapment efficiency and in vitro drug release. They 
proposed  Rifampicin  encapsulated  in  Niosomes  could 
successfully used in the treatment of Tuberculosis51.
20) J.N.Khandare et.al., prepared and evaluated Nimesulide niosomes 
for topical application. Nimesulide was enrtrapped in Niosomes 
prepared  by  various  surfactant  cholesterol  ratio’s  by  Ether 
injection method. Anti – inflammatory activity was evaluated by 
Paw oedema method. The niosomal gel show better activity over 
marketed formulation52.
21) Toshimitsu  Yoshika  et.al.,  prepared  and  studied  about  the 
properties  of vesicles  of Span 20,40,60, 80 and 85. Niosomes 
were  formulated  using  Mechanical  shaking  technique  without 
sonication. Carboxfluorescein (CF) was used as model solute to 
investigate  entrapment  efficiency  and  release.  Most  efficient 
entrapment efficiency was shown with Span 6053.
22) Maria Manconi et.al.,  prepared Tretinoin loaded Niosomes.   The 
Niosomes were prepared from polyoxyethylene (4) lauryl ether, 
sorbitan  ester  and  a  commercial  mixture  of  octy1/decy1 
polyglucosides in the presence of cholesterol and phosphate. A 
study was done on the side, entrapment efficiency and in vitro 
drug release54.
23) N.Udupa  et.al.,  studied  about  the  Anti-inflammatory  activity  of 
Niosome  encapsulated  Diclofenec  sodium  in  rats.  Niosomes 
prepared by using various Non-ionic  surfactants such as Span 
40,60,80,Tween  40,60,80  and  Brij  35  with  cholesterol.  The 
Niosomes were subjected for size and invitro diffusion studies. 
The  Anti-inflammatory  activity  was  checked  by  Paw oedema 
method  Intra-peritonelly  injected  Niosomes  showed  high  paw 
oedema reduction than other routes55.
24) N.K.  Jain  et.al.,  studied  about  the  salient  features  of  niosomes 
including  in-vivo behaviour and in-vivo characterization such as 
vesicle  diameter,  entrapment  efficiency  and  in-vitro  drug 
release56. 
25) R.  Agarwal  et.al.,  prepared and evaluated Niosomally  entrapped 
dithranol.  Niosomes  were  prepared  by  using  span  60  and 
cholesterol.  In  vitro  permeation  studies  were  done  by  using 
mouse abdominal skin57. 
26) Jia-you fang et.al.,  studied about the effect  of Niosomes on skin 
permeation  of  enoxacin.  The  invitro  permeation  studies  were 
done by franz diffusion cells. Niosomal enoxacin shows higher 
stability when compare to liposomes58. 
27) C.O.  Rentel  et.al.,  studied  about  Niosomes  as  a  novel  peroral 
vaccine  delivery  system.  The  test  was  carried  out  by  using 
BALB/c mice. Ovalbumin was encapsulated in various niosome 
preparations.  Two  different  formulations  were  studied.  Only 
ecapsulation of ovalbumin into wasag 7 (70% stearate sucrose 
ester,  30%  palmitate  sucrose  ester  (40%  mono,  60%, 
di/trimester)  Niosomes  show  significant  increase  in  antibody 
titres. 
28) A.T. Florence et.al., studied about the extrusion of Niosomes from 
capillaries.  This  was  an  approach  for  a  pulsed  drug  delivery 
device. Niosomes were extruded from glass capillaries using air 
pressures of 0.5-5 PSI. The extrusion was affected by size, shape 
and membrane composition of Niosomes59. 
29) Anna M. Fadda et.al., studied about Niosomes as drug carriers for 
Tretinoin. Tretinoin niosomes were prepared by using Span 40, 
60, Brij  30 and Triton CG110. Photostability of tretinoin was 
checked and tretinoin niosomes prepared by Brij 30 and triton 
CG110 showed retardation in the drug photodegradation when 
compare to tretinoin niosomes prepared by using span60. 
30) Behrooz  Nasseri  et.al.,  studied  about  the  elastic  properties  of 
Niosomal membrane when there is change in temperature and 
elastic  properties.  Span  60  and  cholesterol  were  used  for 
Niosomal preparation. The proposed that surface elasticity was 
increased  in  increasing  cholesterol  content  to  some  extent 
(around 40 mol% cholesterol) and further increase decreses the 
surface  elasticity61.
31) Ahmed  S  Guinedi  et.al.,  prepared  and  evaluated  multilamellar 
Niosomes  as  ophthalmic  carriers  of  acetazolamide.  Niosomes 
were studied to see the improvement in law corneal penetration 
and bioavailability character’s Niosomes were prepared by Span 
40, 60 with cholesterol. The prepared Niosomes were subjected 
to size analysis, entrapment efficiency and invitro drug release. 
The  prepared  Niosomes  were  subjected  to  size  analysis, 
entrapment  efficiency  and  invitro  drug  release.  Span  60 
Niosomes  shows  higher  entrapment  efficiency  and  shown 
prolonged decrease in intra ocular pressure62. 
32) Christine  Dufes  et.al.,  prepared glucose  –  targeted  Niosomes  to 
deliver  Vasoactive  intestinal  peptide  (VIP)  to  the  brain. 
VIP/125I  VIP  –  loaded  glucose  bearing  Niosomes  were 
intravenously injected to mice. Brain uptake was determined by r 
–  counting.  HPLC analysis  confirmed  the presence  of  VIP in 
brain  after  administration  of  VIP  loaded  Niosomes.  In 
conclusion glucose bearing vesicles might be therefore a novel 
tool to deliver drugs across the blood brain barrier63. 
33) Abbar  Pardakhty et.al.,  prepared and evaluated in-vitro study of 
Brij Niosomes for delivery of insulin. Niosomes were prepared 
by  Film hydration  method.  Entrapment  of  insulin  in  bilayers 
protect it against proteolytic activity of  α -chymotrypsin, trypsin 
and pepsin in vitro. Maximum protection was seen in Brij  92 
Niosomes.  The  results  indicate  that  Niosomes  could  be 
developed as sustained release oral dosage forms for delivery of 
peptides and proteins such as Insulin64.
34) S.P.  Vyas  et.al  formulated  Niosomes  for  non-invasive  topical 
genetic  immunization  against  hepatitis-B.  Here  Niosomes  for 
topical  DNA delivery was studied.  DNA encoded Hepatitis  B 
surface antigen was encapsulated in niosomes composed of span 
85 and cholesterol were prepared by Reverse phase evaporation 
method.  Niosomes  were  characterized  for  size,  shape  and 
entrapment  efficiency.  The  study  signify  the  potential  of 
Niosomes  as  DNA  vaccine  carriers  for  effective  topical 
immunization65. 
35) Elisabetta Gianasi  et.al.,  formulated Niosomes and evaluated the 
biologically  characterization  of  a  Doxorubicin  –  polymer 
conjugate  (pki).  Niosomes  were  prepared  using  span  60, 
cholesterol and solulan. Niosomes were photographed by using 
optical  and  transmission  electron  microscopy.  Final  result 
showed  Niosomes  are  potential  for  use  in  targeted  cancer 
chemotherapy66. 
CHAPTER - VII
AIM AND PLAN OF THE WORK
“If you’ve ever suffered from the irritating itch of a skin disorder 
take  heart… you’re  not  alone.”  The above sentence  is  popular  in  the 
world now because every year millions of people suffer from some kind 
of skin disorder67. 
Glucocorticosteroids  are  used  topically  for  a  large  variety  of 
dermatological  conditions.  They  benefit  by  virtue  of  their  anti 
inflammatory, immune suppressive, vasoconstrictor and antiproliferative 
actions31,68. 
However,  even though glucocorticoids can be used to  treat  vast 
skin disorders it  also have some side effects.  Moreover the premature 
withdrawal of corticosteroids will result in relapse of the disease. So less 
frequent application of a superpotent corticosteroid in a suitable carrier 
may have prolonged action with less or minimal side effects69. 
To achieve the above aim, niosome is one of the right choice. Since 
they can entrap both hydrophilic and lipophillic drugs, it can be employed 
as a suitable drug carrier for steroidal drugs. 
According  to  structure  activity  relationship  of  steroidal  drugs 
addition of fluorine atom at position 6 and/or 9 enhance the potency of 
steroid. 17th hydroxy group is also important to glucocorticoid activity. So 
glucocorticosteroid Clobetasol propionate is choosen. 
Then  various  Clobetasol  propionate  niosomes  were  prepared  by 
altering the ratios between various non ionic surfactants (span series) and 
cholesterol by three methods such as Thin film hydration method, Ether 
injection method and Hand shaking method. 
The prepared niosomes were subjected to drug content  analysis, 
Entrapment efficiency and Invitro drug release studies. The best niosomal 
preparations  were  subjected  to  size  analysis  by  scanning  electron 
microscopy  and  it  is  formulated  as  gel.  Finally  the  niosomal  gel  and 
marketed gel were subjected to invitro drug release studies and invivo 
animal studies. 
PLAN OF WORK
1. Calibration curve for the drug (Clobetasol propionate)
2. Preparations of Niosomal formulations using various ratios of non 
ionic surfactant and cholesterol by three methods. 
a) Thin film hydration method
b) Either injection method and 
c) Hand shaking method 
3. Determination of entrapment efficiency 
4. Observation of vesicle size by scanning electron microscopy
5. In – vitro diffusion studies of clobetasol propionate niosomes 
6. Formulation  of  the  best  niosomal  formulation  into  gel  form for 
topical drug delivery. 
7. Invitro diffusion studies of niosomal gel preparation, plain gel and 
marketed gel preparation.
8. Stability  studies  of  the  best  niosomes  preparation  from  each 
method. 
9. In-vivo animal  studies  to  check the Anti-inflammatony effect  in 
niosomal gel and marketed gel. 
CHAPTER - VIII
MATERIALS AND EQUIPMENTS 
MATERIALS USED
1. Drug – Clobetasol 
Propionate 
⇒ Apex laboratories 
2. Cholesterol ⇒ S.D fine – chem. Ltd 
3. Sorbitan mono palmitate 
(Span 40)
⇒ S.D. fine – chem. ltd 
4. Sorbitan mono stearate 
(span 60)
⇒ S.D. fine – chem. ltd 
5. Sorbitan mono oleate 
(span 80)
⇒ Loba chemie pvt ltd 
6. Chloroform ⇒ Vinbiotech systems (India)
7. Methanol ⇒ Abstron Chemicals (India)
8. N-Propanol ⇒ Lobachemie. Com
9. Carbopol 934 ⇒ Dr. Milton laboratories (Chennai)
10. Diethyl either ⇒ TKM Pharma
11. Triethanolamine ⇒ Robert Johnson 
12. Glycerol ⇒ Omega laboratory chemicals 
13. Propylene glycol ⇒ Robert Johnson 
EQUIPMENTS USED 
1. Rotary flash evaporator ⇒ Super fit rotary flash 
evaporator modrobs 
2. Ultra sonicator ⇒ Vibronic’s ultrasonic 
processor p2
3. Electronic balance ⇒ A & D company, Japan
4. Magnetic stirrer ⇒ MC Daldal & Co
5. UV – Visible 
spectrophotometer 
⇒ UV Pharma spec 1700 
shimadzu
6. pH meter ⇒ Dalal
7. Scanning electron microscopy ⇒ JEOL JSM – 6360
8. Refrigerator ⇒ Kelvinator 
9. Syringe and Needle ⇒ Dispovan 
CHAPTER - IX
DRUG PROFILE
CLOBETASOL PROPIONATE70,71,72,73,74,75,76
GENERAL DESCRIPTION 
CHEMICAL NAME 
21 – chloro – 9 –Fluoro – 11 β  – hydroxyl – 16 β  methy1 3, 20 – 
dioxopregna – 1, 4 – dien-17 – y1 propanoate.
STRUCTURE 
Figure – 7
MOLECULAR FORMULA
C25H32CIFO5
MOLECULAR WEIGHT
467
CHIRALITY  
The molecule has eight chiral centres
CATEGORY 
Topical superpotent corticosteroid
PHARMACOLOGICAL ACTIONS
Anti  –  inflammatory,  Anti  –  pruritic  and  Vaso  constrictive 
properties.
USES 
Alopecia areata; 
Dermatitis, a topic, moderate to severe;
Dermatitis, exfoliative, generalized;
Dermatitis, nummular, moderate to severe;
Dermatoses, inflammatory, other, moderate to severe;
Dermatitis, other forms of, moderate to severe;
Granuloma annulare;
Keloids, reduction of association itching; 
Lichen planus;
Lichen striatus;
Lupus erythenmatosus, discoid and subacute cutaneous;
Myxedema, pretibial;
Necrobiosis lipoidica diabeticorm;
Pemphigoid;
Pemphigus;
Pityriasis rosea;
Psoriasis;
Sarcoidosis; or 
Sunburn 
DOSAGE FORMS 
Ointment, Gel, Foam, Cream, Shampoo, Solution
DOSE 
Usual Adult Dose 
Topically, to the skin as a 0.05% two (or) three times a day.
Usual Pediatric Dose 
Children upto 12 years of age – use is not recommended 
DESCRIPTION 
White or almost white crystalline powder 
SOLUBILITY
Practically insoluble in water, Freely soluble in acetone, sparingly 
soluble in ethanol (96%) 
MELTING RANGE 
Approximately 1960C
SPECIFIC ROTATION 
Between +980 and + 1040
LOSS ON DRYING 
Not more than 2.0%
RESIDUE ON IGNITION 
Not more than 0.1%
STORAGE AND PACKAGING 
Store below 400C (1040F) preferably between 15 and 300C (59 and 
860F) in a well closed container
CLINICAL PHARMACOLOGY
Mechanism of Action
Clobetasol  propionate acts by the induction of phospholipase A2 
inhibitory proteins collectively called lipocortins. Thes lipocortins control 
the  potent  mediators  of  inflammation  such  as  prostaglandins  and 
leukotrienes  by  inhibiting  the  release  of  their  common  precursor 
arachidonic acid. 
PHARAMACOKINETICS 
Absorption
Clobetasol  propionate can be absorbed from normal  skin.  While 
inflammation  and/or  other  disease  processes  in  the  skin  may  enhance 
percutaneous absorption. 
Distribution 
Following topical absorption only a small amount of drug appears 
to reach the dermis and subsequently to reach systemic circulation. 
Metabolism
Presence  of  a  substituted  group  in  17th position  and  fluorinated 
group retards its local metabolism in skin.
Excretion
Clobetasol and its metabolites are excreted in bile and urine.
ADVERSE EFFECTS 
Systemic Effects 
Systemic effects may produce reversible hypothalamic – pituitary – 
adrenal axis, cushing syndrome, hyperglycemia and glucosuria. 
Local Effects 
Atropy  of  the  epidermis,  cracking  cum  tightening  of  skin, 
epidermal  thinning,  telangiectasia,  purpura  and atrophic  striae  may  be 
seen. 
PRECAUTION 
Patient receiving large doses should be evaluated periodically for 
evidence of HPA axis suppression. The following tests are done to access 
the HPA axis suppression. 
i) ACTH stimulation test 
ii) A.M plasma cortisol test
iii) Urinary free cortisol test
CONTRA – INDICATION 
Clobetasol  propionate  is  contraindicated  to  patients  having 
hypersensitivity  to  Clobetasol  propionate  or  any  component  of  the 
preparation. 
CHAPTER – X
EXCIPIENT PROFILE 
CHOLESTEROL77
SYNONYMS
Cholesterin, Cholesterolum
CHEMICAL NAME
Cholest -5- en-3β -ol.
EMPIRICAL FORMULA
C27 H46 O
MOLECULAR WEIGHT
386.67
FUNCTIONAL CATEGORY
Emolient.
Emulsifying agent.
DESCRIPTION
• Cholesterol occurs as white or faintly yellow, almost odurless, 
pearly leaflets, needles, powder or granules.
• On prolonged exposure to light and air, it acquires a yellow to 
tan color.
PROPERTIES
Boiling Point 360oC
Density 1.052 g/cm3 for anhydrous form
Melting Point 1470C - 150oC
Solubility Soluble  in  acetone  and  vegetable  oils. 
Practically  insoluble  in  water.  In 
chloroform, 1 in 4.5 at 20oC, In methanol, 
1 in 294 at 0oC.
STABILITY AND STORAGE CONDITIONS
It  is  stable  and  should  be  stored  in  a  well-closed  container, 
protected from light.
SAFETY
It is generally regarded as an essentially non-toxic and non-irritant 
material at the levels employed as an excipient.
HANDLING PRECAUTIONS
Rubber  or  plastic  gloves,  eye  protection  and  a  respirator  are 
recommended.
SORBITAN MONOPALMITATE77
SYNONYMS
Ablunol S-40, Armotan  MP, Liposorb P, Span 40,  Arlacel 40, 
Montane 40,  Sorbitan Palmitate.
CHEMICAL NAME
Sorbitan monohexa decanoate.
EMPIRICAL FORMULA
C22  H42  O6
MOLECULAR WEIGHT
403
DESCRIPTION
It occurs as cream solid with a distinctive odour and taste.
METHOD OF MANUFACTURE
Sorbitol is dehydrated to form a hexitan(1,4 Sorbitan) which is then 
esterified with the desired fatty acid.
PROPERTIES
Acid value 3 to 7
Hydroxyl value 270 to 303
Iodine valure ≤ 1
Density (g/cm3) 1.0
HLB Value 6.7
Melting point 430C - 48oC
Solubility Soluble in oils and in most organic 
solvents. Insouble but dispersible in 
water.
FUNCTIONAL CATEGORY:
♦ Emulsifying agent.
♦ Non ionic Surfactant.
♦ Solubilizing agent.
♦ Wetting agent.
STABILITY
♦ Gradual soap formation occurs with strong acids or bases.
♦ Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
It is generally regarded as non-toxic and non-irritant material.
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
SORBITAN MONOSTEARATE77
SYNONYMS
Ablunol S-60,  Alkamuls SMS, Sorgen 50,  Tego SMS, Span 60, 
Arlacel 60, Durtan 60, Montane 60, Sorbitan Stearate.
CHEMICAL NAME
Sorbitan mono – Octadecanoate.
EMPIRICAL FORMULA
C24 H46 O6
MOLECULAR WEIGHT 
          431
DESCRIPTION
It occurs as a cream solid with a distinctive odour and taste.
METHOD OF MANUFACTURE
Sorbitol is dehydrated to form a hexitan(1,4 Sorbitan) which is then 
esterified with the desired fatty acid.
PROPERTIES
Acid value 5 to 10
Hydroxyl value 235 to 260
Iodine value ≤ 1
HLB Value 4.7
Melting Point 530C – 57oC
Solubility Soluble  in  oils  and  in  most  organic 
solvents.  Insoluble but dispersible In 
water.
FUNCTIONAL CATEGORY
♦ Emulsifying agent.
♦ Nonionic  Surfactant.
♦ Solubilizing agent.
♦ Wetting agent.
STABILITY
♦ Gradual Soap formation occurs with strong acids or bases.
♦ Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
♦ It  is  generally  regarded  as  non  toxic  and  non  irritant 
material.
♦ Very mildly toxic by ingestion.
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
SOBITAN MONO OLEATE77
SYNONYMS
Ablunol S-80, Armotan MO, Capmul O, Crill 4, Lamesorb SMO, 
Span 80, Arlacel  80, Montane 80, Sorgen 40, Sorbitan Oleate.
CHEMICAL NAME
(Z) - Sorbitan mono -9- Octa decenoate.
EMPIRICAL FORMULA
C24 H44 O6
MOLECULAR WEIGHT
429
DESCRIPTION
It  occurs  as  yellow viscous  liquid  with  a  distinctive  odour  and 
taste.
METHOD OF MANUFACTURE
Sorbitol is dehydrated to form a hexitan(1,4 Sorbitan) which is then 
esterified with the desired fatty acid.
PROPERTIES
Acid value ≤ 8
Hydroxyl value 193 to 209
Pour point 12
Density (g/cm3) 1.01
HLB Value 4.3
Solubility Soluble in oil and in most organic solvents. 
Insoluble but dispersible in water.
Soluble in oil and in most organic solvents. Insoluble but dispersible in 
water.
FUNCTIONAL CATEGORY:
♦ Emulsifying agent.
♦ Nonionic surfactant.
♦ Solubilizing agent.
♦ Wetting agent.
STABILITY:
♦ Gradual soap formation occurs with strong acids or bases
♦ Stable in weak acids or bases.
STORAGE:
It should be stored in a well-closed container in a cool, dry place.
SAFETY:
It is generally regarded as non-toxic and non-irritant material.
HANDLING PRECAUTIONS:
Eye protection and Gloves are recommended.
CARBOMER77
SYNONYMS
Acritamer,  Carbopol,  acrylic  acid  polymer,  carboxy 
polymethylene, polyacrylic acid, carboxy vinyl polymer.
AVAILABLE GRADES
Carbomer 910.
Carbomer 934. 
Carbomer 940. 
Carbomer 971 P.
Carbomer 974 P.
MOLECULAR WEIGHT
        7,00,000 to 4 billion
FUNCTIONAL CATEGORY
Bioadhesive.
Emulsifying agent.
Release-modifying agent.
Suspending agent.
Tablet binder.
Viscosity- increasing agent.
DESCRIPTION
Carbomers are White-colored, ‘fluffy’ acidic, hygroscopic powders 
with a slight characteristic odor.
PROPERTIES
Density 1.76 -2.08 g/cm3
Melting Point Decomposition occurs within 30 min at 260oC
Moisture content Normal  water  content  is  upto  2%  w/w, 
hygroscopic.  Typical  equilibrium  moisture 
content at 25oC.
Solubility Souble in water, after neutralization in ethanol 
(95%)  and glycerin.
Specific gravity  1.41
Viscosity Carbomers disperse in water to form  acidic 
colloidal  dispersions  of  low  viscosity  that 
when neutralized produce highly viscous gels. 
STABILITY
Carbomers are stable, hygroscopic materials  that may be heated at
 temperatures  below  104oC  for  upto  2  hours  without  affecting  their 
thickening efficiency.
STORAGE
 Carbomer powder should be stored in air tight, corrosion-resistant 
container in a cool, dry place.  The use of glass, plastic or resin-lined 
container is recommended.
SAFETY
Carbomers  are  used  extensively  in  non-parenteral   products, 
particularly  topical liquid and semi-solid preparations.  It is generally 
regarded as essentially non- toxic and non- irritant materials.
HANDLING PRECAUTIONS
Carbomer dust  is irritating to the eyes, mucous membranes and 
respiratory  tract.   Gloves,  eye  protection  and  a  dust  respirator   are 
recommended during handling.
CHAPTER – XI
EXPERIMENTAL DETAILS 
PREPARATON OF CALIBRATION CURVE
50 mg of drug was taken in a 50 ml standard flask and dissolved in 
a small amount of methanol. Finally the solution was made upto 50 ml 
with the same methanol.
Then 10 ml of the above solution was pipetted out into an another 
100 ml standard flask and made up to 100ml by methanol. 
Then  from  above  solution  1,2,3,4,5….10  ml  solutions  were 
pipetted out into 10 different 100ml standard flasks and made up to 100 
ml by distilled water.
Aliquant portions of solution was scanned in spectrophotometer to 
find λ max. Then the absorbance of various dilutions were measured at λ 
max (242 nm) in the UV-visible spectrophotometer, using distilled water 
as blank and standard curve was plotted by taking concentration in X-axis 
and absorbance in Y-axis. 
PREPARATION OF CLOBETASOL PROPIONATE NIOSOMAL 
FORMULATIONS
 Different  ratios  of  surfactant  and  cholesterol  were  prepared  as 
shown in Table no – IV A,B,C with same concentration of the drug.
Niosomes of Clobetasol propionate was prepared by three methods. 
They are as follows. 
a. Thin film hydration method 
b. Ether injection method and
c. Hand shaking method 
A. Thin Film Hydration Method79,80
 Surfactant, cholesterol and drug were weighed separately and taken 
in to two different  beakers. 
 15 ml of  Chloroform:  Methanol (2:1)  mixture was added to the 
surfactant : cholesterol mixture and stirred until it gets completely 
dissolved.
 Then the above solution was added to drug and stirred until the 
drug gets completely dissolved. 
 Now the above organic layer was introduced into the round bottom 
flask of Rotary flash evaporator by vacuum.
 The Round Bottom Flask was allowed to rotate at 180 rpm at 600C 
in a water bath until the organic layer was completely evaporated. 
 After  evaporation,  the  surfactant,  cholesterol  and drug formed a 
thin film on the inner sides of Round Bottom Flask. 
 Then water was incorporated into round bottom flask by vacuum 
and allowed to vortexed for 1 hour.
 The thin film layer was peeled out and swelled in water to form 
Niosomes. 
 The above white dispersion (Niosomes) was cooled in an ice bath 
and then sonicated using probe  type ultrasonicator  for  3  min  at 
150v.
 The  resulted  vesicles  of  niosomes  were  stored  at  40C  in  a 
refrigerator.
Plain niosomes were also prepared without drug using the above 
procedure. 
B. Ether Injection Method81
 Here the surfactant, cholesterol and drug were weighed separately 
and  dissolved  by  using  10ml  of  Diethyl  ether:  Methanol  (1:1) 
mixture.
 The above organic layer was taken in an 50 ml syringe having 14 
guaze needle fitted in it.
 Then in an separate beaker adequate amount of distilled water was 
taken  and  it  was  placed  over  a  magnetic  stirrer  and  kept  in  a 
temperature between 550C and 650C.
 Aqueous layer was rotated by using a magnetic bead.
 The above organic layer was injected into swrilling aqueous phase 
at a rate of 0.25 ml / min.
 Vapourization of ether and methanol resulted in the formation of 
niosomes. 
 Finally the niosomes were stored at 40C in a refrigerator.
Plain niosomes were also prepared without drug using the above 
procedure. 
C. Hand Shaking Method82
 Here the surfactant, cholesterol and drug were weighed separately.
 10ml  of  Chloroform:  Methanol  (1:1)  mixture  was  added  to 
surfactant, cholesterol mixture and stirred until it dissolved and the 
above solution was added to the drug and stirred until completely 
dissolved. 
 The above organic layer was transferred to the round bottom flask 
by vacuum.
 The round bottom flask was vortexed at 600C until all the organic 
liquid was completely evaporated. 
 After that adequate amount of the aqueous phase (Distilled water) 
was added and shaken by hands in an water bath at 600C until a 
white dispersion was formed (Niosomes).
Plain niosomes were also prepared without drug using the above 
procedure. 
DRUG CONTENT ANALYSIS79,83,84
Drug  content  of  the  niosomal  preparations  were  determined  by 
lysis method. 50% n-propanol was used for lysing the niosomes. 1ml of 
the  niosomal  formulation  was  taken  in  100ml  standard  flask.  Then 
adequate amount of 50% n-propanol was added and shaken well until all 
the vesicles were completely lysed. The volume was made upto 100ml 
with distilled water.  10ml of the above solution was further diluted to 
100ml with the same distilled water. Now the absorbance was measured 
at 242 nm by UV-spectrophotometer shimadzu using plain niosomes as 
blank. 
ESTIMATION OF ENTRAPMENT EFFICIENCY82,83
Entrapment  efficiency  was  found  out  by  dialysis  method.   The 
Cellophane membrane was used as a semipermeable membrane. Here the 
cellophane membrane was soaked in Glycerol: water (1:3) mixture for 15 
min. It was tied in an open ended tube and 2ml of Niosomal solution was 
transferred into it. The was is placed into a 250ml beaker containing 100 
ml Distilled water  and it  was stirred by magnetic  stirrer.  The samples 
were taken every 15 min for 6 hours. The absorbance was measured at 
242  nm  by  UV-spectrophotometer  shimadzu  using  distilled  water  as 
blank  and  the  entrapment  efficiency  was  calculated  by  the  following 
formula.
Entrapment efficiency = % Drug content - % of maximum drug release of 
unentrapped drug.
SIZE ANALYSIS OF NIOSOMES82
The  niosomes  were  subjected  to  microscopic  examination  for 
characterization size and shape of the vesicles. The vesicles size of the 
prepared  niosomes  were  analysed  by  Scanning  Electron  Microscopy 
(SEM).
IN-VITRO RELEASE STUDIES85,80
Drug Release studies of Clobetasol propionate was done in distilled 
water. The pH of normal health human is between 4.5 and 6. However 
with increase in age the skin pH becomes more and more neutral and thus 
more susceptible to bacterial growth and also the pH value rises beyond 
6, when a person actually suffers from a skin problem (or) skin disease. 
So the  Drug Release  studies  of  Clobetasol  propionate  Niosomes  were 
done in distilled water78. 
 
In  vitro  release  studies  were  carried  out  by  dialysis  method. 
Cellophane membrane was soaked in Glycerin : water (1:3) mixture for 
15 min. It was tied in an open ended tube and to this 1.5 ml of niosomal 
solution was added and then it was placed into a receptor compartment 
i.e; a 250 ml beaker containing 100 ml of distilled water and it was stirred 
by magnetic stirrer. The samples were taken periodically for 8 h. 
The  absorbance  was  measured  at  242  nm  by  UV-
spectrophotometer  shimadzu  (UV-1700  Pharma  spec,  Japan)  using 
distilled  water  as  blank  to  find  the  amount  of  drug  release  from the 
niosomal preparations. The percentage drug released was plotted against 
time to find the drug release behaviour of all niosomal formulations.
STABILITY STUDIES86 
The  best  niosomal  preparations  were  stored  in  two  different 
temperatures such as 40C + 20C and 300C + 20C and the drug content was 
estimated  every  week  for  a  period  of  10  weeks  and  the  results  were 
tabulated. 
FORMULATION OF VARIOUS GEL’S 
From the in-vitro release  studies,  the  best  niosomal  formulation 
was selected and incorporated into suitable gel base. The prepared Gel 
containing plain drug and drug incorporated in niosomes.
The gel base was prepared using the following formula.
Carbopol 934     -   2.0 %
Triethanolamine -   1.65 ml 
Purified water -   100 ml
(freshly boiled and 
Cooled)  
Carbopol 934 was weighed and dispersed in 100 ml purified water  at 
room temperature by constant stirring. The Triethanolamine was added 
and stirred until a viscous smooth gel was obtained. 
A. Preparation of Plain Clobetasol Propionate Gel (G1)86
The  quantity  of  pure  Clobetasol  propionate  (in  methanol) 
equivalent to 0.1 % w/w (50 mg) was incorporated with 10 g of carbopol 
gel base by trituration and stirred by using a glass rod to get 0.05 % w/w 
of smooth homogenous Clobetasol propionate plain gel.
B. Preparation of Niosomal Clobetasol Propionate Gel (G2)86
Formulation 1[Span 60: Cholesterol (1:0.5)] was selected for the 
preparation of gel. The selection was based on the results of entrapment 
efficiency. Since F1 has more entrapment efficiency when compared to 
all  the  other  formulations,  it  was  selected  to  prepare  niosomal  gel. 
Niosomal gel equivalent to 0.1% w/w concentration was incorporated to 
the gel  base  and stirred using glass  rod to  get  0.05% w/w of smooth 
homogenous Clobetasol propionate niosomal gel.
 DRUG CONTENT STUDIES OF GELS79,83
A. Plain Clobetasol Propionate Gel: 
The gel containing 1 mg of drug was weighed and transferred to an 
100ml  standard  flask.  To  this  a  small  quantity  of  distilled  water  was 
added and shaked well and made upto 100ml with distilled water. Then 
10ml of the above solution was diluted to 100ml with the same distilled 
water. 
The  absorbance  was  measured  at  242  nm  by 
UV-spectrophotometer Shimadzu CUV-1700 pharma spec, Japan) using 
plain gel solution prepared by the above method as blank. 
B. Clobetasol Propionate Niosomal Gel G2:
The equivalent to 1mg of drug was weighed and transferred to 100 
ml standard flask.  The adequate amount 50% propanol was added and 
shaken  well  until  the  niosomes  were  lysed  completely.  Finally  the 
solution was made upto 100 ml with distilled water. 10ml of the above 
solution was diluted to 100ml with the same distilled water. 
The  absorbance  was  measured  at  242  nm by  using  UV-visible 
spectrophotometer shimadzu (UV-1700 pharma spec, Japan) using plain 
niosomal solution prepared by above method as blank. 
INVITRO RELEASE STUDIES OF GELS (G1, G2, G3) 80,85 
Invitro release studies was done in plain Clobetasol propionate gel, 
two  Clobetasol  propionate  niosomal  gels  and  marketed  Clobetasol 
propionate gel. 
Invitro release studies were carried out by dialysis method using 
cellophane membrane as a semi permeable membrane. 
Cellophane membrane was soaked in Glycerin water (3:1) mixture 
for  15  min.  Then  it  is  tied  in  a  open  ended  tube  and  3  g  of  gel  is 
transferred into it. The open ended tube was kept as donar compartment. 
Then it was immersed into an 250ml beaker containing 100ml of distilled 
water and kept as recipient compartment. 
The contents were uniformly rotated by a magnetic bead at 50rpm 
at  370c  + 20c.  Then  the  samples  were  withdrawn  at  predetermined 
intervals. Finally the absorbance was measured at 242 nm by using UV-
spectrophotometer  shimadzu  (UV-1700  pharma  spec,  Japan)  using 
distilled  water  as  blank.  The  percentage  release  was  calculated  and 
plotted against time. The percentage release of drug from all the gels was 
compared.
PHARMACODYNAMIC STUDIES OF GEL 
FORMULATIONS79,85,89,90,91 
The Anti-inflammatory  activity  was carried out  by  paw oedema 
method. 
MATERIALS AND METHODS 
Animals : Albino rats of wistar strain (150-200g) of either sex were 
procured  and  kept  in  standard  polypropylene  cages  and  kept  under 
controlled room temperature overnight. The rats were given a standard 
laboratory diet, water and libitium. Food was withdrawn 12 hours before 
and after the experimental hours. 
Drugs 
Plain Clobetasol propionate gel (marketed), Clobetasol propionate 
niosomal gel and carrageenanan. 
Anti-Inflammatory Study
The animals were divided into three groups having four animals in 
each group. Group-I is kept as control without drug. For Group II and 
Group  III  Clobetasol  propionate  niosomal  gel  and  plain  Clobetasol 
propionate gel (marketed) were applied in the right hind paw of the rats 
respectively. After half an hour of the gel application for all the animals 
0.1ml of 1% carrageenan in normal saline was injected in sub plantar on 
the same right hind paw of the rats. Then the paw oedema was measured 
by using plethysmometer at 0, 1, 2, 3, 4, 6 and 8 hours respectively. 
Mean paw oedema was measured and percentage of inhibition was 
calculated. 
CHAPTER – XII
RESULTS AND DISCUSSION 
In  the  present  study,  eighteen  formulations  of  Clobetasol 
propionate Niosomes were prepared by using non-ionic surfactants (Span 
40,60 and 80) along with Cholesterol in different ratios of (S:C) (1:0.5 
and 1:1)  with the concentration of  the  drug being constant  (5  mg)  as 
shown in Table no – IV A,B,C. 
CALIBRATION CRUVE
Calibration  curve  of  Clobetasol  propionate  was  plotted  by 
measuring  the  absorbance  of  different  concentrations  of  the  drug  in 
distilled water at 242 nm. The calibration curve was used to determine the 
drug content, entrapment efficiency, release studies and stability studies 
of  niosomes.  Clobetasol  propionate  obeys  beer’s  law  within  the 
concentration range of 1 to 10 µg/ml and posses a λ max at U.V region of 
242 nm. The results were present in Table - III and figure 8.
ENTRAPMENT EFFICIENCY 
The entrapment efficiency of the prepared niosomal formulations 
was  measured  by  dialysis  method.  The  entrapment  efficiency  was 
determined by subtracting the amount  of  drug dialysed from the total 
amount of drug in the formulation and the values are given in 
Table no – V and Figure 9A, 9B, 9C. 
In all the formulations, the impact of Cholesterol, surfactant and 
method of preparations on entrapment efficiency was significant. 
Effect of Cholesterol Content
The formulations with increased cholesterol ratio (F2, F4, F6, F8, 
F10, F12, F14, F16 and F18) showed decrease in entrapment efficiency 
compared with other formulations. The results are shown in Table - V 
and  figure  9A,  9B,  9C.  This  revealed  that  the  increase  in  cholesterol 
content  decreases  the  entrapment  efficiency  which  may  be  due  to 
intercalation of cholesterol in the bilayers.82
Effect Of Surfactant 
Among  all  the  formulations  F1  [span  60:  cholesterol  (1:0.5)] 
showed  maximum  entrapment  efficiency  compared  with  other 
formulations35.  The  entrapment  efficiency  increases  in  the  order  of 
span 60 > span 40 > span 80. The results are shown in Table V and 
figure 9A, 9B, 9C.
The  results  showed  that  entrapment  efficiency  increases  with 
decrease in HLB value of non-ionic surfactant with an exception of span 
80 because it has unsaturated alkyl chain compared to span 60.80,53
Further span 60 showed higher entrapment efficiency than the span 
40 due to the higher phase transition temperature of Span 60 than that of 
Span 40.83
Effect Of Method 
Among all the three methods Thin film Hydration method showed 
maximum entrapment efficiency compared with other formulations. The 
entrapment efficiency increases in order of Thin film hydration method 
> Hand shaking  method > Ether injection method.  The  results  are 
shown in Table no: V and figure 9A, 9B, 9C.
The amount of entrapment efficiency by Hand shaking method was 
more than ether  injection method.  This  may be due to vortexing only 
which was carried out during hand shaking method, whereas in the case 
of  ether  injection  process  vortexing  and  injection  take  place 
simultaneously. Moreover the vesicles obtained by hand shaking method 
were  larger  when  compared  to  vesicles  obtained  by  ether  injection 
method. So due to this entrapment efficiency was more in hand shaking 
method when compared with ether injection method49.
The entrapment efficiency of the Thin film hydration method was 
more, when compared with hand shaking method. This may be due to 
uniform and mechanical vortexing in Thin film hydration method. 
SIZE ANALYSIS OF NIOSOMES 
The  vesicle  size  of  the  prepared  niosomes  were  observed  and 
measured by Scanning Electron Microscopy. Most of the vehicles were 
found  to  be  spericalin  shape  and  in  size  ranges  from 50  to  200  nm. 
However the size of niosomes in Hand shaking method was larger when 
compared  with  the  Thin  film  hydration  method  and  ether  injection 
method.
INVITRO RELEASE STUDIES 
The invitro release studies of all span niosomal formulations were 
carried out by diffusion method and the percentage of drug released from 
these  formulations  are  shown  in  table  no:  VI  A,  B,  C  and  Figure 
10A, B, C 
A. Effect of Entrapment Efficiency 
a. Thin Film hydration method 
Among all the six formulations from F1 to F6, F1 shows maximum 
drug release and the order of decreasing percentage drug release in 24th 
hour are F1 (49.76%) > F5(42.44%) > F6 (36.09%) > F4 (32.69%) > F3 
(28.41%)  >  F2  (22.30%)  The  results  are  shown  in  Table  VI-A  and 
Figure 10A.
b. Ether injection method
Among  all  the  six  formulations  from  F7  to  F12,  F10  shows 
maximum drug release and the order of decreasing percentage of drug 
release in 24th hour are F10 (42.44%) > F11 (39.70%) > F9 (37.06%) 
> F8 (35.17%) > F7 (30.93%) > F12 (27.43%). The results are shown in 
table VI-B and Figure 10B.
c. Hand shaking method 
Among  all  the  six  formulations  from  F13  to  F18,  F13  shows 
maximum  drug  release  and  the  order  of  decreasing  percentage  drug 
release in 24th hour are F13 (41.78%) > F15 (36.66%) > F17 (35.76%) 
> F18 (32.21%) > F14 (28.93%) > F16 (26.68%) The results are shown in 
table VI-C and 10C.
B. Effect of Surfactant And Cholesterol.
a. Thin film hydration method 
Among all the six formulations from F1 to F6, F1 shows maximum 
drug release35 and the order of decreasing percentage drug release in 24th 
hour are [S60: Chol (1:0.5) – 49.76%] > [S80 : chol (1:0.5) – 42.44%] 
> [S80:chol  (1:1)  -  36.09%] > [S40:chol (1:1)  -  32.69%] > [S40:chol 
(1:0.5) – 28.41%] > [S60:chol (1:1) – 22.30%].  The results are shown in 
Table VI A and Figure 10A. 
b. Ether injection method 
Among  all  the  six  formulations  from  F7  to  F12,  F10  shows 
maximum  drug  release  and  the  order  of  decreasing  percentage  drug 
release in 24th hour are [S40:chol (1:1) – 42.44%] > [S80:chol (1:0.5) 
39.70%]  >  [S40:chol  (1:0.5)  -  37.06%]  >  [S60:chol  (1:1)  –  35.17%] 
> [S60:chol (1:0.5) -30.93%] > [S80:chol (1:1) – 27.43%]. The results are 
shown in table VI-B and Figure 10B.
C. Hand Shaking Method
Among  all  the  six  formulations  from  F13  to  F18,  F13  shows 
maximum  drug  release  and  the  order  of  decreasing  percentage  drug 
release in 24th hour are [S60:chol (1:0.5) – 41.78%] > [S40:chol (1:0.5) 
– 36.66%] > [S80:chol (1:0.5) – 35.76%] > [S80:chol (1:1) – 32.21%] 
> [S60:chol (1:1) – 28.93%] > [S40:chol (1:1) – 26.68%]. The results are 
shown in table VI-C and figure 10C.
STABILITY OF NIOSOMES 
The stability of the best formulation in each group of surfactant 
(High entrapment efficiency) F1, F7 and F13 were carried out by storing 
at  40C  + 20C  (refrigeration  temperature)  and  300C  + 20C  (room 
temperature) for 10 weeks. 
The  retention  of  drug  in  niosomal  formulations  was  calculated 
immediately after the preparation and was taken as 100% retention. The 
percentage of drug retention in the niosomal preparation at various time 
intervals was determined. The results are shown in table no: VII-A, VII-B 
and figure 11a, 11b and 11c.
The results showed that the drug retention capacity was at 40C  + 
20C but increase in temperature and storage period decreases the drug 
retention capacity. 
GEL FORMULATION 
The selected  best  niosomal  formulation (on the basis  of  highest 
entrapment efficiency among all the three methods) was incorporated into 
suitable  gel  base  (carbopol)  to  obtain  0.05%  of  the  drug  and  plain 
Clobetasol  propionate gel was prepared by incorporating the drug into 
suitable gel base to obtain same 0.05% of the drug. Both the formulas 
were tabulated in Table VIII A and VIII B.
Drug Content
The drug content of the prepared gels was determined after lysing 
the vesicles. It was estimated spectrophotometricaly at 242 nm in UV-
visible 1700-pharma spec, Japan. The results are shown in Table IX. The 
uniform distribution of drug in all the gel formulations was observed. 
In-Vitro Release Studies
In vitro release studies were performed for the gels prepared with 
the carbopol base and compared with the marketed product (0.05% gel) 
From the results shown in table – X marketed product (G3) showed 
98.43% release in 300 min. The carbopol gel containing pure drug (G1) 
showed 99.12% release in 360 min as shown in Table X and figure 12. In 
case of carbopol gel containing niosomes showed 51.58% release in 24th 
hour. This shows the release of drug was controlled due to the entrapment 
of drug in vesicles. The results are shown in Table X and figure 12. The 
increase in order of release is G3 > G1 > G2. 
PHARMACODYNAMIC STUDY OF GEL FORMULATIONS90,89
The  pharmacodynamic study was carried out to find out the anti-
inflammatory activity of niosomal gel preparation (G2) and to correlate it 
with marketed gel formulation. It was assessed by carrageenan induced 
hind paw oedema method in white albino rats. 
After  Studying  the  anti  inflammatory  activity,  the  percentage 
inhibition of oedema by clobetasol propionate niosomal gel and marketed 
gel were compared with their respective control groups, statistically by 
students ‘t’ test. The results were shown in Table XI-A, XI-B and Figure 
13.
The  percentage  of  reduction  in  paw  oedema  was  gradually 
increasing  in  the  case  of  niosomal  gel  upto  8th hour  and  whereas  in 
marketed gel the percentage of reduction in paw oedema was gradually 
increasing upto 4th hour and later it declined on 6th and 8th hour. 
The above results showed niosomal gel had a sustained as well as 
prolonged action when compared with marketed gel.
CHAPTER XIII
SUMMARY AND CONCLUSION 
 Clobetasol  propionate  niosomes  were  prepared using  surfactants 
span 40, 60 and 80 in two different ratios by three methods. 
 The  niosomal  formulations  were  characterized  for  their  vesicle 
size, entrapment efficiency and invitro release study. 
 The entrapment efficiency was found to be highest for niosomal 
formulation  (F1)  when  compared  with  other  niosomal 
formualtions. 
 The  shape  of  Clobetasol  propionate  niosomes  are  spherical  in 
nature and the size ranges between 50 and 200 nm.
 The invitro release study showed prolonged release profile for all 
the  eighteen  niosomal  formulations  and  F1  showed  more  drug 
release at 24th hour. 
 On the basis of entrapment efficiency and invitro release study, the 
niosomal formulation (F1) equivalent to 0.05% w/w of clobetasol 
propionate was incorporated into carbopol gel base and evaluated 
with 0.05% w/w of plain clobetasol propionate gel and marketed 
gel  having same 0.05% of clobetasol  propionate.  The gels  were 
easy to prepare and found to be homogenous in composition. 
 The  invitro  release  studies  of  clobetasol  propionate  gel 
formulations revealed that the release rate of clobetasol propionate 
from  niosomal  gel  was  slower  than  that  of  plain  clobetasol 
propionate gel and marketed gel.
 Pharmacodynamic  activity  of  clobetasol  propionate  gel  showed 
uniform and prolonged anti-inflammatory activity when compared 
to marketed gel preparations. Therefore the present study suggests 
the potentiality of noisomes to enhance the therapeutic effect and 
minimize the side effects of clobetasol propionate. 
From the above study it  is  concluded that  the niosomes can be 
considered  as  promising  drug  delivery  vehicles  which  increase  the 
duration  of  action  of  the  drugs.  Thus  niosomes  help  in  formulating 
dosage forms having more prolonged action. The niosomal delivery of 
clobetasol propionate in carbopol gel base acts as a suitable topical drug 
delivery system which may be given safely to all patients suffering from 
skin disorders (above 12yrs). The gel produces smoothness and cooling 
effect with more compatibility with the skin surface. 
Further  the  pharmacokinetic  and  other  clinical  studies  may  be 
carried out in future. 
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